Orange Book product · Brand (NDA)
EMEND
APREPITANT
At a glance
Dec 17, 2015
Approved
Brand (NDA)
Application
Not listed
TE code
1
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Dec 17, 2015
10 yr 8 mo ago
Today
Patent 8258132 expires
Listed drug product patent expiration.
Sep 26, 2027
in 1 yr 3 mo
Pharmaceutical detail
Active ingredient
APREPITANT
Strength
125MG/KIT
Dosage form
FOR SUSPENSION
Route
ORAL
TE code
Not listed
Application
NDA 207865
Product number
001
Marketing status
RX
Reference listed drug (RLD)
Yes
Reference standard (RS)
Yes
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
- 2022APONVIEBrand (NDA)
NDA 216457 · HERON THERAPS INC
- 2017CINVANTIBrand (NDA)
NDA 209296 · HERON THERAPS INC
- 2006EMENDBrand (NDA)
NDA 021549 · MSD
- 2026APREPITANTGeneric (ANDA)
ANDA 218851 · MYLAN
- 2020APREPITANTGeneric (ANDA)
ANDA 211835 · TORRENT
- 2017APREPITANTGeneric (ANDA)
ANDA 207777 · GLENMARK SPECLT
- 2012APREPITANTGeneric (ANDA)
ANDA 090999 · SANDOZ
Listed patents (1)
| Patent | Expires | In | Type |
|---|---|---|---|
| 8258132 | Sep 26, 2027 | in 1 yr 3 mo | ProductU-1916 |

